Jožef M.
- Country
- Slovenia
- Department
- Department of neurology
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Ofatumumab Efficacy and Patient-Reported Outcomes in Relapsing Multiple Sclerosis Patients Transitioning from Fumarate-Based Therapies or Fingolimod
- A Randomized, Double-Blind, Parallel-Group Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension
Data & Insights
Has run more than one trial at 87 of 253 partner sites.
Specializations
Neurology and Multiple Sclerosis
This investigator specializes in the treatment of relapsing multiple sclerosis (RMS), with particular focus on evaluating innovative therapeutic approaches for patients experiencing breakthrough disease.
- Treatment-resistant RMS
- Disease modification strategies
- Treatment transitions
Their expertise extends to managing patients transitioning between different therapeutic options in RMS treatment.
Therapeutic Innovation
The investigator's work encompasses the evaluation of novel therapeutic agents for multiple sclerosis, including targeted immunomodulatory treatments.
- Monoclonal antibody therapies
- BTK inhibitors
- Comparative treatment efficacy
Their research interests include investigating therapeutic alternatives for patients with suboptimal response to conventional treatments.
Clinical Outcomes
The investigator focuses on assessing treatment effectiveness through comprehensive evaluation of clinical outcomes and patient responses.
- Relapse reduction strategies
- Patient-reported outcomes
- Treatment optimization
Their work emphasizes the importance of monitoring disease progression and treatment response in MS patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.